161 related articles for article (PubMed ID: 34015010)
21. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
22. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
[TBL] [Abstract][Full Text] [Related]
23. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
26. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
27. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
[TBL] [Abstract][Full Text] [Related]
28. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
30. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: a pilot study.
Basile U; Miele L; Napodano C; Ciasca G; Gulli F; Pocino K; De Matthaeis N; Liguori A; De Magistris A; Marrone G; Biolato M; Marino M; Di Giacinto F; Gasbarrini A; Grieco A; Rapaccini GL
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12675-12685. PubMed ID: 33378014
[TBL] [Abstract][Full Text] [Related]
32. Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development.
Caviglia GP; Abate ML; Troshina G; Carucci P; Rolle E; Risso A; Burlone ME; Albè A; Crevola M; Musso EC; Rosso C; Armandi A; Olivero A; Minisini R; Saracco GM; Bugianesi E; Pirisi M; Ciancio A; Gaia S
Biology (Basel); 2023 Jan; 12(1):. PubMed ID: 36671786
[TBL] [Abstract][Full Text] [Related]
33. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
34. Abnormal prothrombin: evaluation as a tumour marker and localization in tissues of patients with hepatocellular carcinoma.
Koda T; Yamazaki S; Tamura I; Nakaba H; Takao T; Katayama S; Kurimura O
J Gastroenterol Hepatol; 1993; 8(3):212-6. PubMed ID: 7686054
[TBL] [Abstract][Full Text] [Related]
35. Des-gamma carboxy prothrombin (PIVKA-II) and alpha-fetoprotein producing gastric cancer with multiple liver metastases.
Takahashi Y; Inoue T
Pathol Int; 2003 Apr; 53(4):236-40. PubMed ID: 12675768
[TBL] [Abstract][Full Text] [Related]
36. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
[TBL] [Abstract][Full Text] [Related]
37. Solitary Muscle Metastasis of Hepatocellular Carcinoma to the Biceps Femoris Muscle with Only Elevated Serum PIVKA-II: A Case Report.
Orita K; Sakamoto A; Okamoto T; Matsuda S
Am J Case Rep; 2019 Mar; 20():306-309. PubMed ID: 30846677
[TBL] [Abstract][Full Text] [Related]
38. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.
Saitta C; Raffa G; Alibrandi A; Brancatelli S; Lombardo D; Tripodi G; Raimondo G; Pollicino T
Medicine (Baltimore); 2017 Jun; 96(26):e7266. PubMed ID: 28658121
[TBL] [Abstract][Full Text] [Related]
39. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
Qin X; Tang G; Gao R; Guo Z; Liu Z; Yu S; Chen M; Tao Z; Li S; Liu M; Wang L; Hou L; Xia L; Cheng X; Han J; Qiu L
Int J Lab Hematol; 2017 Aug; 39(4):392-401. PubMed ID: 28318145
[TBL] [Abstract][Full Text] [Related]
40. PIVKA-II-producing advanced gastric cancer.
Takano S; Honda I; Watanabe S; Soda H; Nagata M; Hoshino I; Takenouchi T; Miyazaki M
Int J Clin Oncol; 2004 Aug; 9(4):330-3. PubMed ID: 15375711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
